Revenue Growth - Total revenue for Q4 2024 was $18.5 million, a 41% increase from $13.1 million in Q4 2023[4] - Full year 2024 revenue reached $65.4 million, a 45% increase compared to $45.2 million in 2023[8] - Product revenue for Q4 2024 was $14.1 million, up 41% from $10.0 million in Q4 2023[4] - Subscription revenue for Q4 2024 was $4.4 million, representing a 40% increase from $3.1 million in Q4 2023[4] - The company expects 2025 revenue to be in the range of $81 million to $85 million, representing growth of approximately 24% to 30%[13] Profitability and Loss - Gross profit for Q4 2024 was $16.2 million, with a gross margin of 88%, compared to 85% in Q4 2023[5] - Operating expenses for Q4 2024 were $29.1 million, a 49% increase from $19.5 million in Q4 2023[6] - Net loss for Q4 2024 was $12.6 million, or $0.40 per share, compared to a net loss of $8.3 million, or $1.53 per share, in Q4 2023[7] Financial Position - Total current assets increased significantly to $217,272 million in 2024 from $51,963 million in 2023, representing a growth of approximately 318%[22] - Cash and cash equivalents rose to $194,370 million in 2024, up from $34,495 million in 2023, marking an increase of about 465%[22] - Total liabilities increased to $34,247 million in 2024, compared to $23,762 million in 2023, reflecting a growth of approximately 44%[22] - The company reported an accumulated deficit of $(166,944) million in 2024, worsening from $(126,489) million in 2023[22] - Total stockholders' deficit expanded to $191,165 million in 2024, compared to $(112,252) million in 2023, indicating a significant increase in financial strain[22] - The number of issued and outstanding common shares increased to 35,850,606 in 2024 from 5,430,298 in 2023, representing a growth of approximately 560%[22] - Additional paid-in capital surged to $358,073 million in 2024, up from $14,232 million in 2023, indicating a substantial increase in equity financing[22] - Current liabilities decreased to $12,989 million in 2024 from $21,600 million in 2023, a reduction of approximately 40%[22] - Long-term liabilities rose to $21,258 million in 2024, compared to $2,162 million in 2023, reflecting an increase of about 884%[22] - The company has no redeemable convertible preferred stock as of December 31, 2024, compared to a liquidation preference of $152,590 million in 2023[22] Operational Highlights - The company ended 2024 with 529 total active accounts[8] - The company submitted a 510(k) application for the pediatric Clarity™ algorithm to the U.S. FDA[8]
CeriBell, Inc.(CBLL) - 2024 Q4 - Annual Results